Key Points
- Director Rowan Chapman sold 4,366 shares on Dec. 5 at an average price of $243.10 for about $1.06M, cutting his position by 43.04% to 5,777 shares.
- Natera reported Q results with EPS of ($0.64) that missed consensus ($0.39) but revenue of $592.18M beat estimates and rose 34.7% year‑over‑year.
- Analysts have been lifting price targets (e.g., Evercore to $250, BTIG to $260), leaving a consensus "Moderate Buy" and a $225.29 target while the stock trades near its 12‑month high and a ~$32.6B market cap.
Natera, Inc. (NASDAQ:NTRA - Get Free Report) Director Rowan Chapman sold 4,366 shares of the firm's stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $243.10, for a total transaction of $1,061,374.60. Following the transaction, the director owned 5,777 shares of the company's stock, valued at approximately $1,404,388.70. This trade represents a 43.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Natera Price Performance
NASDAQ NTRA opened at $235.53 on Wednesday. Natera, Inc. has a 12 month low of $125.38 and a 12 month high of $246.90. The company has a market capitalization of $32.58 billion, a P/E ratio of -102.85 and a beta of 1.63. The company's 50 day simple moving average is $202.57 and its 200 day simple moving average is $175.16.
Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The company had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. During the same period in the prior year, the company posted ($0.26) EPS. Natera's quarterly revenue was up 34.7% on a year-over-year basis. On average, analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.
Analysts Set New Price Targets
NTRA has been the topic of several recent analyst reports. Barclays boosted their target price on shares of Natera from $210.00 to $230.00 and gave the company an "overweight" rating in a research note on Friday, November 7th. Piper Sandler increased their price objective on Natera from $220.00 to $230.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 11th. Evercore ISI lifted their target price on Natera from $190.00 to $250.00 and gave the company an "outperform" rating in a research note on Friday, November 7th. Canaccord Genuity Group reiterated a "buy" rating and issued a $250.00 target price on shares of Natera in a report on Monday. Finally, BTIG Research raised their price target on shares of Natera from $230.00 to $260.00 and gave the stock a "buy" rating in a report on Friday, December 5th. Fifteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Natera currently has a consensus rating of "Moderate Buy" and a consensus target price of $225.29.
Get Our Latest Stock Analysis on Natera
Institutional Investors Weigh In On Natera
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Allworth Financial LP grew its stake in shares of Natera by 63.3% in the 3rd quarter. Allworth Financial LP now owns 2,373 shares of the medical research company's stock valued at $382,000 after buying an additional 920 shares in the last quarter. IFP Advisors Inc increased its stake in shares of Natera by 36.2% during the 3rd quarter. IFP Advisors Inc now owns 583 shares of the medical research company's stock worth $94,000 after purchasing an additional 155 shares during the last quarter. Swiss Life Asset Management Ltd increased its stake in shares of Natera by 11.0% during the 3rd quarter. Swiss Life Asset Management Ltd now owns 10,270 shares of the medical research company's stock worth $1,653,000 after purchasing an additional 1,017 shares during the last quarter. Investment Research Partners LLC bought a new stake in shares of Natera during the 3rd quarter worth about $171,000. Finally, CIBC Private Wealth Group LLC boosted its holdings in shares of Natera by 44.2% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 173,088 shares of the medical research company's stock worth $27,862,000 after buying an additional 53,086 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.
About Natera
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
